General AML,   FLT3

Prof. Charles Craddock | EBMT 2018 | Can hypomethylating agents prevent post-transplant relapse in AML?


Prof. Charles Craddock (chair of our European Steering Committee) from Queen Elizabeth Hospital, Birmingham, UK, discusses strategies to reduce post-transplant relapse in AML at the 44th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, 18–21 Mar 2018, Lisbon, PT. He noted that delaying the GvL effect using agents such as gilteritinib, sorafenib and azacitidine may be a strategy for reducing post-transplant relapse. 

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF